Future studies will have to address whether betatrophin represents a potential novel drug target for lipid-lowering treatment and/or a cardiovascular risk factor that may suggest close monitoring and post-partum follow up investigations, particularly in women with prior GDM who are known to be at increased cardiovascular risk. Here, ANGPTL8 is linked to gestational diabetes.